Differences in oestrogen and progesterone receptors, HER-2 and p53 expression and proliferation in ductal breast cancers in relation to histopathological grade

• Autorzy: Zaslawski R , Surowiak P. , Paluchowski P. , Dziegiel P. , Maciejczyk A. , Pudelko M. , Wojnar A. , Zabel M.
• Języki publikacji: EN

Abstrakty

EN

In case of breast cancer the grade of differentiation and expression of oestrogen and progesterone receptors falls within the first category of prognostic factors according to the College of American Pathologists. HER-2, p53 and Ki67 belong to the second category and their significance still awaits confirmation. The aim of the present study was to examine the relationship between the intensity of expression of oestrogen receptors (ER), progesterone receptors (PgR), HER-2, p53 and Ki67 in cells of ductal breast cancer of G1, G2 or G3 differentiation grade. In paraffin sections of 60 ductal breast cancers (20 cases in G1, 20 in G2 and 20 in G3), immunocytochemical reactions were performed to detect the expression of ER, PgR, HER-2, p53 and Ki67. Following a semi-quantitative appraisal of the preparations under examination, appropriate statistical tests were used to document significant relationships. We noted significant positive correlations between ER and PgR (the entire group studied, G1–3, and the G1 group), HER-2 and p53 (G2) and between p53 and Ki67 expression (G2). Significant negative correlations were found between ER and p53 (G1–3), PgR and p53 (G1–3, G1, G3) and between PgR and Ki67 (G1–3, G2). The studies performed demonstrated distinct relationships between the expression intensity of various proteins in tumour cells in relation to the grade of differentiation of the tumour. We also showed that a parallel determination of ER, PgR and p53 expression may carry high predictive value as to response to tamoxifen treatment.

Słowa kluczowe

EN

estrogen receptor; progesterone receptor; proliferation; breast cancer; cancer; histopathology; immunocytochemistry; prognostic factor

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2005
• Tom: 64
• Numer: 1
• Opis fizyczny: p.9-15,fig.,ref.

Twórcy

autor

Zaslawski R

• Voivodship Hospital, Legnica, Poland

autor

Surowiak P.

autor

Paluchowski P.

autor

Dziegiel P.

autor

Maciejczyk A.

autor

Pudelko M.

autor

Wojnar A.

autor

Zabel M.

Bibliografia

• 1. Allred DC, Bustamante MA, Daniel CO (1990) Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg, 125: 107–113.
• 2. Dzięgel P, Forgacz J, Suder E, Surowiak P, Kornafel J, Zabel M (2003) Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol, 18: 401–407.
• 3. Elston CW, Ellis IO (1991(Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopatology, 19: 403–410.
• 4. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connoly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologist Consensus Statement 1999. Arch Pathol Lab Med, 124: 966–978.
• 5. Heinaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand of mutations. Adv Cancer Res, 77: 81–137.
• 6. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG (2000) Hormone-related factors and risk of breast cancer in relation to estrogen and progesterone receptor status. Am J Epidemiol, 151: 703–714.
• 7. Jensen EV, Cheng G, Palinmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci, 98: 15197–15202.
• 8. Keshigegian AA, Cnaan A (1996) Estrogen receptornegative, progesterone receptor-positive breast carcinoma. Poor clinical outcome. Arch Pathol Lab Med, 120: 970–973.
• 9. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 330: 1260–1266.
• 10. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J (2000) The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88: 804–813.
• 11. Remmele W, Stenger HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe, 8: 138–140.
• 12. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Human Pathol, 26: 873–879.
• 13. Scholzen T, Gerdes J (2000) The Ki67 protein: from the known and the unknown. J Cell Physiol, 182: 311–322.
• 14. Slamon DJ, Clark GM, Wong SG (1987) Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science, 235: 177–182.
• 15. Surowiak P, Dzięgiel P, Zabel M, Matkowski R, Kornafel J (2001) Prognostic value of immunocytochemical estimation of estrogen receptor (ER) and of pS2 estrogen-dependent protein in cells of mammary ductal carcinoma. Analysis of five-year course of the disease. Fol Histochem Cytobiol, 39: 143–144.
• 16. Warnberg F, Nordgren H, Bergkvist L, Holmberg L (2001) Tumour markers in breast cancer correlate with grade rather than with invasiveness. Br J Cancer, 85: 869–874.
• 17. Zasławski R, Surowiak P, Dzięgiel P, Prętnik L, Zabel M (2001) Analysis of the expression of estrogen and progesteron receptors, and of PCNA and Ki67 proliferation antigens, in uterine myomata cells in relation to the phase of the menstrual cycle. Med Sci Monit, 7: 784–789.